These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: In vitro correction of the interleukin 2 defect of autoimmune mice.
    Author: Santoro TJ, Luger TA, Ravache ES, Smolen JS, Oppenheim JJ, Steinberg AD.
    Journal: Eur J Immunol; 1983 Jul; 13(7):601-4. PubMed ID: 6603367.
    Abstract:
    The effect of concanavalin A (Con A) and/or phorbol myristate acetate (PMA) on interleukin 2 (IL 2) production and tritiated thymidine incorporation was measured in young (6 weeks) and old (16-24 weeks) autoimmune mice by pulsing 5 X 10(6) unfractionated spleen cells with 5 micrograms of Con A and/or 5 ng of PMA for variable periods of time. The apparent deficiency in Con A-stimulated IL 2 production manifested by mice prone to the development of autoimmune disease was repaired by the addition of PMA. PMA did not enhance interleukin 1 (IL 1) secretion in autoimmune MRL-lpr mice either alone or in combination with Con A. The addition of purified IL 1 to Con A-pulsed autoimmune cells did not increase IL 2 production. Freeze-thaw experiments suggested that PMA does not promote IL 2 synthesis. Con A-pulsed cells plus PMA-pulsed cells do not syngergize. These data indicate that autoimmune-prone mice are capable of producing IL 2 and of proliferating in response to Con A provided the comitogen PMA is present. It can be argued that the failure to produce IL 2 or to respond to proliferative signals is not fundamental to the development of the disease sustained by autoimmune-prone mice.
    [Abstract] [Full Text] [Related] [New Search]